Biogen Inc.
BIIBHealthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) P/E ratio
As of 6 November 2026, Biogen Inc. (BIIB) trades at a P/E ratio of 105×. Over the past ten years it has ranged from 7.7× (July 2020) to 108× (November 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 26.5× and above the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 19.9× | 46.24% |
| FY2024 | 13.6× | (59.12%) |
| FY2023 | 33.3× | 156.68% |
| FY2022 | 13.0× | (43.53%) |
| FY2021 | 23.0× | 130.16% |
| FY2020 | 10.0× | 6.16% |
| FY2019 | 9.4× | (32.30%) |
| FY2018 | 13.9× | (50.36%) |
| FY2017 | 28.0× | 73.82% |
| FY2016 | 16.1× | (19.15%) |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 95.7× | 151.55% |
| Jun 2026 | 38.0× | 94.00% |
| Mar 2026 | 19.6× | (1.62%) |
| Dec 2025 | 19.9× | 56.37% |
| 43 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GILD Gilead Sciences, Inc. compare | n/m |
| NVO Novo Nordisk A/S compare | 10.1× |
| BMY Bristol Myers Squibb Company compare | 13.7× |
| GSK GSK PLC Sponsored ADR compare | 16.7× |
| SNY Sanofi compare | 23.3× |
| AZN AstraZeneca PLC compare | 26.2× |
| AMGN Amgen Inc. compare | 26.5× |
| PFE Pfizer Inc. compare | 41.3× |
| BIIB Biogen Inc. | 105× |
| Drug Manufacturers General industry median | 26.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement